Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease

P. F. Vollebregt | A. A. van Bodegraven | T. M. L. Markus-de Kwaadsteniet | D. van der Horst | R. J. F. Felt-Bersma

Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands

Department of Gastroenterology, Geriatrics, Internal Medicine and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Heerlen-Geleen-Sittard, The Netherlands

Dutch Crohn’s and Colitis organisation (CCUVN), Woerden, The Netherlands

Correspondence
Dr. P. F. Vollebregt, Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands.
Email: p.vollebregt@vumc.nl

Summary
Background: Patient reported outcomes regarding perianal disease and faecal incontinence in the community-based inflammatory bowel disease population are poorly described.
Aims: To determine the impacts of perianal disease and faecal incontinence on quality of life and employment in inflammatory bowel disease patients.
Methods: For this cross-sectional study, a comprehensive survey was sent out to members of the Dutch National Crohn’s and Colitis patient organisation. Validated questionnaires regarding faecal incontinence and active perianal disease were used to estimate its prevalence. The effect on the quality of life (36-Item Short Form Survey) and on employment status (multivariate binary regression analysis) was assessed in this inflammatory bowel disease population.
Results: A total number of 1092 returned questionnaires (58% responders) were used for analysis; 750 respondents (69%) were female; mean age was 47 years (IQR 35-59). In 621 patients (57%) Crohn’s disease, in 422 (39%) ulcerative colitis and in 49 (4%) patients unclassifiable inflammatory bowel disease was self-reported. The 114 patients (10%) with a stoma were excluded for continence related analyses. Faecal incontinence was reported in 555 patients (57%), was comparable between the different inflammatory bowel disease diagnoses and affected all 36-Item Short Form Survey subscales adversely (incontinence vs continence: Physical functioning 75 vs 84, \( P < 0.0001 \); Limitations due to physical health 49 vs 63, \( P < 0.0001 \); Limitations due to emotional problems 49 vs 64, \( P < 0.0001 \); Energy/fatigue 47 vs 53, \( P < 0.0001 \); Emotional well-being 71 vs 74, \( P = 0.005 \); Social functioning 63 vs 73, \( P < 0.0001 \); Pain 66 vs 75, \( P < 0.0001 \); General health 41 vs 48, \( P < 0.0001 \)). Active perianal disease was reported in 39% Crohn’s disease, 16% ulcerative colitis (84% fissures) and 20% unclassifiable inflammatory bowel disease patients. Faecal incontinence was more common in patients with perianal disease (67% vs 53%, \( P = 0.003 \)). When correcting for age, disease duration, inflammatory bowel disease-related surgery and faecal incontinence, active perianal disease was independently affecting employment (OR 0.67; 95% CI 0.50-0.91; \( P = 0.01 \)).
Conclusions: Faecal incontinence and perianal disease are quality of life determining factors. Faecal incontinence needs more attention among clinicians, and development of new (drug) therapies needs to be focussed on perianal disease.
1 | INTRODUCTION

Inflammatory bowel disease (IBD) mainly comprises Crohn’s disease (CD) and ulcerative colitis (UC). It is well known that these relatively common conditions consume significant healthcare resources,1,2 and may compromise patient’s quality of life.3 As the diseases are chronic, symptoms of most concern to the patients have to be characterised and treatment needs to be guided by quality of life above all else. However, a large proportion of patients is not able to express potentially important information to their physician with regard to their complaints,7 and almost 50% report that their physician does not ask about the impact of their symptoms on quality of life.4 Awareness amongst clinicians is needed regarding complaints causing the highest burden in this population, to prioritise treatment and development of new therapeutic strategies.

Faecal incontinence, usually defined as the uncontrolled loss of liquid or solid stool, is one of the concerns reported by IBD-patients.5 Its prevalence amongst the IBD-population, which has only been investigated in five studies to date, is estimated between 20% and 38% in tertiary centers6–9 and even up to 74% in a community-based population.10 The latter has only been reported once, precluding reliable data on community-based prevalence numbers of faecal incontinence and its association with quality of life. In a cross-sectional study, only 3% of patients had a medical diagnosis of faecal incontinence, whilst 36% reported complaints.11 Indisputably, the anal function warrants (medical) attention and physicians (gastroenterologist and colorectal surgeons, in particular) need to ask actively.

Perianal disease (ie, fissures, fistulas, abscesses and stenosis) occurs in a considerable group of patients with CD, and is associated with a more extensive and complicated disease behaviour.12 The prevalence of these, usually embarrassing, complaints is reported in a wide range, partly due to a variety of used definitions.13 The limited number of studies addressing this have mainly focussed on tertiary populations,14 hence a community-based, more accurate estimation has barely been reported.15,16 If documented, anal pain and discomfort seem unfavourable factors compromising quality of life,17 and self-reported depressive symptoms are frequently concurrently observed,18 underlining the negative impact on quality of life.

In this cross-sectional study, we aimed to survey the prevalence of faecal incontinence and perianal disease, and related its occurrence with perceived quality of life, in a large population-based cohort of members of the Dutch Crohn’s and Colitis patients’ organisation (CCUVN).

2 | METHODS

2.1 | Study population

In October 2016, CCUVN had a total membership database of 10 047 patients. A comprehensive, anonymised study questionnaire (Data S1) was sent out online (via a purpose-designed secure website) by the CCUVN in January 2015 and October 2016 to a panel which consisted of 1710 CCUVN patients (1206 female) in October 2016. The panel is represented by patients who gave consent to participate in online surveys with regard to disease-related subjects, which are carried out several times a year. A reminder was sent out to non-responders after 3 weeks. In addition, a link to the questionnaire was added to the monthly CCUVN newsletter of January 2015. Inclusion criteria were age over 18 years old and a self-reported diagnosis of IBD.

2.2 | Questionnaires

The close-ended survey included a self-reported IBD diagnosis (CD, UC or ‘IBD-U’ if the type of disease was not classifiable by the patient, or if UC was reported with the presence of small bowel disease), perianal disease activity index,19 St. Marks incontinence score,20 36-Item Short Form Survey21 and the faecal incontinence quality of life questionnaire.22 Faecal incontinence was defined as the involuntary loss of liquid or solid stool at least once per month. Active perianal disease was described as a score of ≥1 for the category “Type of perianal disease” on the perianal disease activity index. An additional questionnaire was developed to collect data with regard to basic and disease characteristics, and previously performed (IBD-related) surgical interventions.

2.3 | Statistical analysis

Patients with CD, UC and IBD-U were characterised by the use of descriptive statistics. Continuous variables were described as means with interquartile ranges (IQR), categorical variables as percentages. Differences between continuous variables were studied with the use of the Student’s t test and chi-square was used for categorical variables. One-way ANOVA was used for comparison of continuous variables between ≥2 groups. All patients had complete data for the basic characteristics (age, sex, type of disease [CD, UC, IBD-U], disease localisation and stoma surgery). For variables with missing data, multiple imputation was performed using the Markov Chain Monte Carlo method (total variables missing 2.4%; job description 0.1%; operational procedures 0.6%; age at diagnosis 1.7%; influence of IBD on job description 2.4%; 36-Item Short Form Survey 2.5%; effect of IBD on productivity at work during the past 6 months 3.4%; sick leave during the past 6 months because of IBD 3.6%; St. Marks incontinence score 4.7%; perianal disease activity index 5.8%; faecal incontinence quality of life questionnaire 7.1%). As a total of 52% of patients had a complete dataset, multiple imputations are appropriate technique or imputation of missing data.23 Little’s MCAR test was performed for determining whether missing values were missing completely at random.24 Ten imputed data sets were created and pooled. Patients with a stoma were excluded in continence-related analyses. Basic and disease characteristics which were associated with employment status (P < 0.10) were included in the multivariable logistic regression model to identify independent associated
factors ($P < 0.05$ considered statistical significant), with results presented as effect sizes (Odds Ratio) with 95% CI. Statistical analysis was performed using SPSS Statistics version 21 (IBM Corp, Armonk, NY, USA).

2.4 Ethical statement

This study was initiated by the CCUVN. The members of the selected panel gave consent to participate in anonymous health-related surveys.

3 RESULTS

3.1 Patient population

A total of 1120 patients responded to the questionnaire. Of these patients, 997 (91%) were member of the CCUVN panel, resulting in a response rate of 58%. The other 95 (9%) responded the questionnaire via the CCUVN newsletter. Twenty-eight patients were excluded due to the age of $<18$ years ($n = 14$), lack of information regarding their diagnosis ($n = 11$), and missing basic characteristics ($n = 3$). The remaining 1092 patients were slightly younger (47 vs 48 years; $P = 0.02$) compared to the 9100 CCUVN patients (91%) who registered their age and gender; there was no difference in gender (69% vs 66% females; $P = 0.06$). Demographics, disease characteristics and previously performed IBD-related surgery of the 1092 patients are shown in Table 1 (CD = 621; UC = 422; IBD-U = 49).

Overall, 376 female patients (50%) had at least one vaginal delivery. CD patients were younger than UC patients (46 vs 49 years; $P = 0.001$). They were diagnosed with CD at a younger age than UC patients (32 vs 38 years; $P < 0.0001$), and had a longer disease duration compared to IBD-U patients (14 vs 9 years; $P = 0.011$). CD patients underwent more often IBD-related abdominal surgery (CD 44%; UC 10% and IBD-U 12%; $P < 0.0001$). Active perianal disease was reported by 244 CD patients (39%), 69 UC patients (16%) and 10 IBD-U patients (20%). Of these, a total of 58 UC patients (84%) reported anal fissures only. Perianal surgery was predominantly performed in CD patients (fistula surgery 19%; abscess surgery 20%), although also reported amongst the UC population (fistula surgery 2%; abscess surgery 3%).

3.2 Faecal incontinence

To describe the prevalence of faecal incontinence, all patients with a stoma were excluded (CD = 92, UC = 19, IBD-U = 3). Faecal incontinence was reported in 555 patients (57%) (306 CD patients [58%], 225 UC patients [56%] and 24 IBD-U patients [52%], Table 2). The mean St. Marks incontinence score was higher in CD patients compared to IBD-U patients (9 vs 7; $P = 0.011$). Faecal incontinence was frequently associated with a flare-up in all types of diagnoses (CD 42%; UC 56%; IBD-U 42%), more often in UC compared to CD patients ($P = 0.005$). Furthermore, a total of 125 CD (41%), 78 UC (35%) and 9 IBD-U patients (38%) reported faecal incontinence episodes during periods of remission in addition. Twenty-three per cent of CD patients who underwent perianal surgery reported that symptoms of faecal incontinence were related to the perianal surgery. Quality of life on all of the four faecal incontinence quality of life subscales (ranging 0-4) was affected, regardless the type of diagnosis. As shown in Table 3, incontinent patients reported a lower 36-Item Short Form Survey score on all different subscales compared to continent patients (Physical functioning 75 vs 84, $P < 0.0001$; Limitations due to physical health 49 vs 63, $P < 0.0001$; Limitations due to emotional problems 49 vs 64, $P < 0.0001$; Energy/fatigue 47 vs 53, $P < 0.0001$; Emotional well-being 71 vs 74, $P = 0.005$; Social functioning 63 vs 73, $P < 0.0001$; Pain 66 vs 75, $P < 0.0001$; General health 41 vs 48, $P < 0.0001$). Patients with an age over 65 were excluded to assess the impact of faecal incontinence on daily work. Less incontinent patients reported a paid job (65% vs 74%; $P = 0.002$).

3.3 Perianal disease

Patients from all diagnoses (CD, UC and IBD-U) with perianal disease ($n = 323$) were compared to IBD patients without perianal disease ($n = 769$) with regard to their quality of life, employment and the association with faecal incontinence. Patients with perianal disease reported a lower 36-Item Short Form Survey score on all different subscales (Physical functioning 74 vs 80, $P < 0.0001$; Limitations due to physical health 47 vs 57, $P = 0.001$; Limitations due to emotional problems 47 vs 57, $P = 0.0002$; Energy/fatigue 44 vs 52, $P < 0.0001$; Emotional well-being 69 vs 73, $P = 0.001$; Social functioning 60 vs 69, $P < 0.0001$; Pain 62 vs 72, $P < 0.0001$; General health 39 vs 45, $P < 0.0001$). Restriction of sexual activities was reported amongst more than two-third of the patients with perianal disease (no restriction 31%; slight restriction 28%; moderate limitations 25%; marked limitations 12%; unable to engage in sexual activities 4%).

Patients with an age over 65 were excluded to assess the impact of perianal disease on daily work. Less patients with perianal disease reported a paid job (61% vs 69%; $P = 0.004$), and a higher proportion of patients with perianal disease reported that their job type was a result of their IBD (34% vs 21%; $P < 0.0001$). Patients with perianal disease were more likely to report sick leave during the past 6 months (48% vs 36%; $P = 0.007$), and the effect of their IBD on their work productivity during the past 6 months was reported to be higher on a 0-10 Likert scale (4.6 vs 3.9; $P = 0.01$).

Subsequently, patients with a stoma were excluded to analyse the prevalence and impact of faecal incontinence on quality of life in IBD patients with perianal disease compared to other IBD patients. Faecal incontinence was more commonly reported amongst patients with perianal disease compared to patients without perianal disease (67% vs 53%; $P = 0.003$). In addition, incontinent patients with perianal disease reported a lower quality of life on all of the four different faecal incontinence quality of life subscales.
TABLE 1 Demographics, disease characteristics and previously performed IBD-related surgery of the total group (n = 1092)

| Variable                                      | Crohn’s disease | Ulcerative colitis | IBD not classifiable by patient |
|-----------------------------------------------|-----------------|--------------------|---------------------------------|
| Number of patients                            | 621 (57%)       | 422 (39%)          | 49 (4%)                         |
| Gender                                        |                 |                    |                                 |
| Female                                        | 459 (74%)       | 262 (62%)          | 29 (59%)                        |
| Vaginal delivery                              | 214 (47%)       | 145 (55%)          | 17 (59%)                        |
| 1                                             | 71 (33%)        | 44 (30%)           | 8 (47%)                         |
| 2                                             | 104 (49%)       | 84 (58%)           | 6 (35%)                         |
| 3                                             | 29 (14%)        | 12 (8%)            | 0                               |
| 4                                             | 9 (4%)          | 3 (2%)             | 3 (18%)                         |
| >4                                            | 1 (0.5%)        | 2 (2%)             | 0                               |
| Male                                          | 162 (26%)       | 160 (38%)          | 20 (41%)                        |
| Age—years<sup>a</sup> (mean, IQR)             | 46 (34-57)      | 49 (37-61)         | 46 (35-57)                      |
| Age at diagnosis—years<sup>b</sup> (mean, IQR) | 32 (30-41)      | 38 (26-48)         | 37 (29-46)                      |
| Disease duration—years<sup>c</sup> (mean, IQR) | 14 (10-19)      | 12 (3-19)          | 9 (2-13)                        |
| Disease location                              |                 |                    |                                 |
| Oesophagus/stomach                            | 44 (7%)         | 0                  | 3 (6%)                          |
| Small bowel                                   | 173 (28%)       | 6 (12%)            | 0                               |
| Large bowel                                   | 181 (29%)       | 357 (85%)          | 30 (61%)                        |
| Rectum                                        | 142 (23%)       | 65 (15%)           | 16 (33%)                        |
| Small and large bowel                         | 244 (39%)       | 0                  | 9 (18%)                         |
| IBD-related abdominal surgery<sup>d</sup>     | 272 (44%)       | 40 (10%)           | 6 (12%)                         |
| Bowel resection                               | 219 (35%)       | 8 (2%)             | 3 (6%)                          |
| Subtotal colectomy                            | 31 (5%)         | 18 (4%)            | 2 (4%)                          |
| Ileal pouch-anal anastomosis                  | 11 (2%)         | 11 (3%)            | 1 (2%)                          |
| Abscess                                       | 56 (9%)         | 3 (0.7%)           | 0                               |
| Stoma                                         | 92 (15%)        | 19 (5%)            | 3 (6%)                          |
| Active perianal disease                       |                 |                    |                                 |
| No                                            | 377 (61%)       | 353 (84%)          | 39 (80%)                        |
| Yes                                           | 244 (39%)       | 69 (16%)           | 10 (20%)                        |
| Perianal surgery                              |                 |                    |                                 |
| Fistula                                       |                 |                    |                                 |
| Surgery                                       | 121 (19%)       | 8 (2%)             | 2 (4%)                          |
| Seton                                         | 61 (10%)        | 1 (0.2%)           | 0                               |

As faecal incontinence was more commonly reported amongst patients with perianal disease, a multivariate binary regression analysis was performed to investigate the independent impact of both complaints on employment status. The results in Table 5 show that perianal disease (Odds Ratio 0.71; 95% CI 0.53-0.95; P = 0.02) and faecal incontinence (Odds ratio 0.68; 95% CI 0.51-0.90; P = 0.007) are both independently affecting employment status (no paid job = 0 vs paid job = 1), when corrected for the presence of a stoma. Table S1 shows a univariate analysis of all basic characteristics and other factors with a possible effect on employment status. Age (Odds ratio 0.95; 95% CI 0.94-0.96; P < 0.0001), age at diagnosis (Odds ratio 0.98; 95% CI 0.97-0.99; P < 0.0001), disease duration (Odds ratio 0.96; 95% CI 0.95-0.97; P < 0.0001), subtotal colectomy (Odds ratio 0.31; 95% CI 0.16-0.57; P = 0.0002), Ileal pouch-anal anastomosis (Odds ratio 0.47; 95% CI 0.20-1.12; P = 0.09), abdominal abscess surgery (Odds ratio 0.53; 95% CI 0.30-0.92; P = 0.02), stoma (Odds ratio 0.63; 95% CI 0.41-0.95; P = 0.03), active perianal disease (Odds ratio 0.66; 95% CI 0.50-0.88; P = 0.004), perianal surgery (Odds ratio 0.63; 95% CI 0.45-0.90; P = 0.01) and faecal incontinence (Odds ratio 0.65; 95% CI 0.49-0.86; P = 0.002) were all affecting employment status.

Disease duration and age at diagnosis (P < 0.0001), and active perianal disease and perianal surgery (P < 0.0001) were highly correlated variables, therefore age at diagnosis and perianal surgery were not added to the final model. In the multivariate model (Table S1), age (Odds ratio 0.96; 95% CI 0.94-0.97; P < 0.0001), subtotal colectomy (Odds ratio 0.37; 95% CI 0.17-0.80; P = 0.01) and active perianal disease (Odds ratio 0.67; 95% CI 0.49-0.91; P = 0.01) were independently affecting employment status. Faecal incontinence lost its effect in this model (P = 0.15) due to the addition of age, as incontinent patients were older compared to continent patients (47 vs 42 years; P < 0.0001).
In this community-based IBD population, we observed that more than half of patients reported involuntary loss of faeces at least once per month, regardless of their diagnosis. Even if all nonresponders would be classified as continent, which seems implausible, still 35% of the population would report symptoms of faecal incontinence. Other key findings were that active perianal disease was frequently reported amongst the CD (39%) population, and that regular episodes of faecal incontinence were more common in patients with active perianal disease. Furthermore, faecal incontinence and active perianal disease were affecting quality of life on all 36-Item Short Form Survey subscales, and active perianal disease (corrected in a multivariate regression analysis) had a negative effect on employment status.

| TABLE 2 | Prevalence of faecal incontinence (≥ monthly) and associated quality of life. Patients with a stoma were excluded in this analysis |
|----------|--------------------------------------------------------------------------------------------------------------------------------|
| Variable                  | Crohn’s disease | Ulcerative Colitis | IBD not classifiable by patient | P-value |
| Stoma                    | No              | 529 (85%)          | 403 (95%)          | 46 (94%)          | <0.0001* |
| Female                   | 397 (75%)       | 251 (62%)          | 27 (59%)           |                     |
| Male                     | 132 (25%)       | 152 (38%)          | 19 (41%)           |                     |
| Yes                      | 92 (15%)        | 19 (5%)            | 3 (6%)             |                     |
| Faecal incontinence      | Number of patients | 306 (58%)          | 225 (56%)          | 24 (52%)          | 0.60     |
| Female                   | 242 (79%)       | 162 (72%)          | 13 (54%)           |                     |
| Vaginal delivery         | 129 (53%)       | 97 (60%)           | 8 (62%)            |                     |
| Male                     | 64 (21%)        | 63 (28%)           | 11 (46%)           |                     |
| Liquid stool             | ≥ monthly, < weekly | 161 (53%)          | 196 (87%)          | 21 (88%)           |         |
| Liquid stool             | ≥ weekly        | 40 (13%)           | 22 (10%)           | 2 (8%)             |         |
| Solid stool              | ≥ monthly, < weekly | 102 (33%)          | 83 (37%)           | 10 (42%)           |         |
| Solid stool              | ≥ weekly        | 9 (1%)             | 9 (4%)             | 1 (4%)             |         |
| St. Marks incontinence score (mean, IQR) | 9 (7-12)       | 9 (7-11)           | 7 (5-8)            | 0.011** |
| Related to:              | Flare           | 130 (42%)          | 125 (56%)          | 10 (42%)          | 0.005*  |
| Remission                | 125 (41%)       | 78 (35%)           | 9 (38%)            | 0.40               |
| Nutrition                | 71 (23%)        | 47 (21%)           | 1 (4%)             | 0.09               |
| Perianal surgery         | 15 (23%)        | 1 (8%)             | 0                    |                     |
| Faecal incontinence quality of life (mean, IQR) | 3.0 (2.4-3.7)   | 2.9 (2.3-3.5)      | 2.8 (2.2-3.5)      | 0.16               |
| Lifestyle                | Coping/behaviour | 2.3 (1.7-2.8)     | 2.3 (1.8-2.8)      | 2.3 (1.7-2.9)     | 0.68     |
| Depression/self-perception | 2.8 (2.3-3.3)  | 3.0 (2.6-3.4)      | 2.8 (2.3-3.2)      | 0.30               |
| Embarrassment            | 2.8 (2.3-3.3)   | 3.0 (2.3-3.3)      | 2.8 (2.3-3.3)      | 0.14               |

* Differences between Crohn’s disease and ulcerative colitis remained significant after Bonferroni correction (P < 0.017).
** Differences between Crohn’s disease and IBD-unknown remained significant after Bonferroni correction (P < 0.017).

**DISCUSSION**

In this community-based IBD population, we observed that more than half of patients reported involuntary loss of faeces at least once per month, regardless of their diagnosis. Even if all nonresponders would be classified as continent, which seems implausible, still 35% of the population would report symptoms of faecal incontinence. Other key findings were that active perianal disease was frequently reported amongst the CD (39%) population, and that regular episodes of faecal incontinence were more common in patients with active perianal disease. Furthermore, faecal incontinence and active perianal disease were affecting quality of life on all 36-Item Short Form Survey subscales, and active perianal disease (corrected in a multivariate regression analysis) had a negative effect on employment status.

Community-based numbers of faecal incontinence in IBD patients have sparsely been described; in one study, a prevalence of faecal incontinence up to 74%, was reported, based on a questionnaire with a response rate of only 33%.10 The authors estimated a prevalence of 24% if all nonrespondents were classified as continent. In a tertiary population, faecal incontinence may be more prevalent, as these patients may have more a complicated disease course which potentially increases the risk of faecal incontinence. A prevalence of 28% in 108 consecutive IBD patients of a tertiary CD out-patient clinic has indeed been reported.7 Twenty-six per cent of a referral out-patient population in South Asia reported complaints of faecal incontinence, in a study in which patients with previous traumatic anal injury, concomitant neurological disorders or psychiatric illnesses were excluded.8 In a previous study, we reported a prevalence of 20% in a complex CD population,9 using the same definition as in this study. These findings imply that the prevalence in this study may be overestimated (albeit still worrisome), which might be explained by a more than average engaged population consisting of self-selected patients being member of a patient organisation, whom already signed up for surveys. Nevertheless, physicians need to be pro-active in questioning IBD patients for symptoms of faecal incontinence, as this distressing complaint is reported by a substantial proportion of patients.
TABLE 3  Quality of life in patients with symptoms of faecal incontinence (≥ monthly) compared to those without

| Variable                  | Incontinent | Continent | P-value |
|---------------------------|-------------|-----------|---------|
| SF-36 (mean, IQR)         |             |           |         |
| Physical functioning      | 75 (65-95)  | 84 (75-100) | <0.0001 |
| Limitations due to physical health | 49 (0-100)  | 63 (25-100) | <0.0001 |
| Limitations due to emotional problems | 49 (0-100)  | 64 (33-100) | <0.0001 |
| Energy/fatigue            | 47 (30-65)  | 53 (35-75) | <0.0001 |
| Emotional well-being      | 71 (60-84)  | 74 (64-88) | 0.005   |
| Social functioning        | 63 (50-75)  | 73 (63-100) | <0.0001 |
| Pain                      | 66 (45-80)  | 75 (68-90) | <0.0001 |
| General health            | 41 (25-55)  | 48 (30-65) | <0.0001 |
| Number of patients ≤ 65 years | 483 (87%)  | 379 (90%) |        |
| Job description           | 0.002*      |           |         |
| No job                    | 121 (25%)   | 67 (18%)  |         |
| Paid job                  | 312 (65%)   | 282 (74%) |         |
| Voluntary work            | 50 (10%)    | 30 (8%)   |         |

*Differences between patients with (65%) and without symptoms of faecal incontinence (74%) with a paid job remained significant after Bonferroni correction (P < 0.017).

Remarkably, faecal incontinence was reported during periods of both flare-ups as well as in remission. In addition, up to one-third of the incontinent patients reported involuntary loss of solid stool, corroborating that faecal incontinence not only occurs during periods of active disease which has not been reported previously in the IBD population. In patients with active disease, diarrhoea and proctitis can be considered as contributing factors to faecal incontinence. In remission, previously performed bowel resections, perianal fistula surgery, and also rectal fibrosis associated with a decreased rectal compliance are associated with an increased risk.4 Besides these disease specific factors, other frequently related causes of faecal incontinence (traumatic delivery, pudendal neuropathy, neurological diseases) may also be responsible for the complaints. If active disease has been excluded, treatment can be started with fibre supplements and physiotherapy ± biofeedback. In patients in whom conservative management has failed, additional anorectal physiology testing (eg, anorectal manometry, rectal sensation/compliance tests, endoanal ultrasonography and defaecography) might be considered, and a multidisciplinary approach with gastroenterologists, gynaecologists and colorectal surgeons can be worthwhile to determine the best treatment strategy.

Perianal disease (fistulas in particular) remains a challenging problem in patients with CD. Since the advent of the tumour necrosis factor antagonists, some improvement of fistula treatment has been achieved. Results from the ACCENT II trial have shown that infliximab is considered effective in up to 36% at a follow-up of 54 weeks,26 and adalimumab therapy was associated with increases in fistula closure over time in the open label-extension study of the CHARM.27 Another recent treatment option is mesenchymal stem cell therapy, which, at week 52, appeared to be beneficial in (not too) complex perianal fistulas in approximately 56% of CD patients as compared to 39% success in controls, who were only operated upon.28 In this patient group, potentially surgical treatment may remain an alternative, but likewise often an unsuccessful therapeutic option. Fissures that are resistant to conservative treatment may also require surgery, such as lateral internal sphincterotomy, which in itself may induce faecal incontinence, particularly in women.29 In addition, the association between anal stenosis and faecal incontinence has been described previously.30

We have shown that patients with perianal disease more frequently reported symptoms of faecal incontinence, which emphasises the demand for development of new nonsurgical treatment options, as perianal surgery in this group is discouraged. Furthermore, patients with active perianal disease reported a diminished quality of life and a higher rate of work disability as a result of their disease. This implied that perianal disease may cause an economic burden.2,31 It needs to be taken into account that more aggressive luminal disease, especially in the colon or rectum, may also play a role in this, as it is related to perianal disease.12 To assess the exact impact of perianal disease on healthcare costs, a health-economics analysis will be needed, as previously performed by the COIN study group.1

We acknowledge that there were methodological limitations to conducting this study. First, the survey was sent to a panel of self-selected CCUVN patients. As approximately 80 000 people in the Netherlands suffer from IBD, one of eight is member of the patient association. The panel consisted of patients who signed up voluntarily to complete disease-related questionnaires. Hence, the group may be represented by patients who are more dedicated to report their complaints or have more severe disease. This potential bias always needs to be considered when health-related outcomes are interpreted. Second, the patients were asked to report their disease characteristics themselves and no additional clinical (or endoscopic) information was used to confirm the diagnosis, previously performed disease-related interventions or current disease activity. Third, we acknowledge the limitations of the perianal disease activity index to assess the prevalence of active perianal disease. From our perspective, this tool is appropriate to indicate whether perianal disease is currently active or not. However, the questionnaire cannot be used to estimate the prevalence of the different types of perianal disease (fissures/fistula), as scores for different types are added up to the same category. Fourthly, we used an online questionnaire to address the research questions, although it has been demonstrated that Internet-respondents generally report a poorer quality of life than patients recruited from clinic.32

Bearing in mind the limitations, we were still able to show the impact of faecal incontinence and perianal disease on quality of life. Assessment of these conditions among the community based population using patient reported outcome according to the terminology of the US Food & Drug Administration has barely been performed to date. To assess the specific effect of these embarrassing complaints, the use of patient reported outcome is essential, as the status of a patient’s health condition is reported without amendment or interpretation by a clinician or by anyone else. As such, this methodology might provide more accurate results on the burden compared to results collected by physicians only.
In conclusion, faecal incontinence and perianal disease are frequently occurring in IBD patients, leading to an unmet need in terms of therapeutic options. Awareness amongst physicians is needed to ask actively for complaints of faecal incontinence, and development of new therapies needs to be focussed on treatment of perianal disease, taking patient reported outcomes into account when describing its efficacy.

TABLE 4 Quality of life and symptoms of faecal incontinence (≥ monthly) in all patients with and without perianal disease. Patients with a functioning stoma were excluded in continence related analyses

| Variable                          | Perianal disease | Non-perianal disease | P-value |
|-----------------------------------|------------------|----------------------|---------|
| Number of patients                | 323 (30%)        | 769 (70%)            |         |
| Crohn’s disease                   | 244 (39%)        | 377 (61%)            |         |
| Ulcerative colitis                | 69 (16%)         | 353 (84%)            |         |
| IBD not classifiable by patient   | 10 (20%)         | 39 (80%)             |         |

Quality of life

SF-36 (mean, IQR)

| Variable                          | Perianal disease | Non-perianal disease | P-value |
|-----------------------------------|------------------|----------------------|---------|
| Physical functioning              | 74 (60-80)       | 80 (70-95)           | <0.0001 |
| Limitations due to physical health| 47 (0-100)       | 57 (0-100)           | 0.001   |
| Limitations due to emotional problems | 47 (0-100)   | 57 (0-100)           | 0.0002  |
| Energy/fatigue                    | 44 (25-60)       | 52 (35-70)           | <0.0001 |
| Emotional well-being              | 69 (56-84)       | 73 (64-88)           | 0.001   |
| Social functioning                | 60 (50-75)       | 69 (50-88)           | <0.0001 |
| Pain                              | 62 (45-78)       | 72 (58-90)           | <0.0001 |
| General health                    | 39 (25-55)       | 45 (30-60)           | <0.0001 |
| Number of patients ≤ 65 years     | 300 (93%)        | 678 (88%)            |         |

Job description

| Variable                          | Univariate Odds Ratio (95% CI) | P-value | Multivariate Odds Ratio (95% CI) | P-value |
|-----------------------------------|--------------------------------|---------|----------------------------------|---------|
| Stoma                             | 0.63 (0.41-0.95)                | 0.03    | 0.68 (0.44-1.03)                 | 0.07    |
| Active perianal disease           | 0.66 (0.50-0.88)                | 0.004   | 0.71 (0.53-0.95)                 | 0.02    |
| Faecal incontinence               | 0.65 (0.49-0.86)                | 0.002   | 0.68 (0.51-0.90)                 | 0.007   |

In conclusion, faecal incontinence and perianal disease are frequently occurring in IBD patients, leading to an unmet need in terms of therapeutic options. Awareness amongst physicians is needed to ask actively for complaints of faecal incontinence, and development of new therapies needs to be focussed on treatment of perianal disease, taking patient reported outcomes into account when describing its efficacy.

ACKNOWLEDGEMENT

Declaration of personal and funding interests: None.

AUTHORSHIP

Guarantor of the article: Richelle J. F. Felt-Bersma.

Author contributions: Paul F. Vollebregt: analysis and interpretation of data, drafting of manuscript, approval final draft of the manuscript. Adriaan A. van Bodegraven: study conception and design, interpretation of data, critical revision of the manuscript, approval final draft of the manuscript. Tineke M. L. Markus-de Kwaadsteniet: study design, data collection, critical revision of the manuscript, approval final draft of the manuscript. Danielle van der Horst: study design, data collection, critical revision of the manuscript, approval final draft of the manuscript. Richelle J. F. Felt-Bersma: study conception and design, interpretation of data, critical revision of the manuscript, approval final draft of the manuscript.

All authors approved the final version of the article, including the authorship list.
REFERENCES

1. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63:72-79.

2. van der Valk ME, Mangen MJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS ONE. 2016;11:e0142481.

3. Lonnfors S, Vermeire S, Greco M, et al. IBD and health-related quality of life – discovering the true impact. J Crohns Colitis. 2014;8:1281-1286.

4. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10-20.

5. de Rooy EC, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. Am J Gastroenterol. 2001;96:1816-1821.

6. Brochard C, Siproudhis L, Leveque J, et al. Factors associated with fecal incontinence in women of childbearing age with Crohn’s disease. Inflamm Bowel Dis. 2017;23:775-780.

7. Enck P, Bielefeldt K, Rathmann W, et al. Epidemiology of faecal incontinence in selected patient groups. Int J Colorectal Dis. 1991;6:143-146.

8. Subasinghe D, Navarathna NM, Samarasekera DN. Faecal incontinence and health related quality of life in inflammatory bowel disease patients: findings from a tertiary care center in South Asia. World J Gastrointest Pharmacol Ther. 2016;7:447-452.

9. Vollebregt PF, Visscher AP, van Bodegraven AA, et al. Validation of risk factors for fecal incontinence in patients with Crohn’s disease. Dis Colon Rectum. 2017;60:845-851.

10. Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis. 2013;7:e302-e311.

11. Dunivan GC, Heymen S, Palsson OS, et al. Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. Am J Obstet Gynecol. 2010;202:e1-e6.

12. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082-3093.

13. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508-1530.

14. Lam TJ, van Bodegraven AA, Felt-Bersma RJ. Anorectal complications and function in patients suffering from inflammatory bowel disease: a series of patients with long-term follow-up. Int J Colorectal Dis. 2014;29:923-929.

15. Eglinton TW, Barclay ML, Garry RB, et al. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum. 2012;55:773-777.

16. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.

17. Mahadev S, Young JM, Selby W, et al. Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum. 2011;54:579-585.

18. Mahadev S, Young JM, Selby W, et al. Self-reported depressive symptoms and suicidal feelings in perianal Crohn’s disease. Colorectal Dis. 2012;14:331-335.

19. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27-32.

20. Vaizey CJ, Carapeti E, Cahill JA, et al. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44:77-80.

21. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160-164.

22. Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43:9-16; discussion 16-7.

23. Eekhout I, de Vet HC, Twisk JW, et al. Missing data in a multi-item instrument were best handled by multiple imputation at the item score level. J Clin Epidemiol. 2014;67:335-342.

24. Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. 1988;83:1198-1202.

25. Rao SS, Bharucha AE, Chiariongi G, et al. Functional anorectal disorders. Gastroenterology. 2016;150:1430-1442.

26. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876-885.

27. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940-948.

28. Panes J, Garcia-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (C601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2017; https://doi.org/10.1053/j.gastro.2017.12.020 [Epub ahead of print].

29. Nyam DC, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum. 1999;42:1306-1310.

30. Linares L, Moreira LF, Andrews H, et al. Natural history and treatment of anorectal strictures complicating Crohn’s disease. Br J Surg. 1988;75:653-655.

31. van der Have M, Fidder HH, Leenders M, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis. 2015;21:369-377.

32. Jones MP, Bratton J, Keefer L. Quality of life in patients with inflammatory bowel disease and irritable bowel syndrome differs between subjects recruited from clinic or the internet. Am J Gastroenterol. 2007;102:2232-2237.

SUPPORTING INFORMATION

Additional Supporting Information will be found online in the supporting information tab for this article.

How to cite this article: Vollebregt PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, Felt-Bersma RJF. Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1253-1260. https://doi.org/10.1111/apt.14599